Pragmatech raises €650k to expand its AI-powered antibiotic prescribing software in the healthcare industry

Pragmatech is a pioneering HealthTech startup from Spain with a strong focus on AI solutions within the realms of pharmacology, microbiology, and infectious diseases. Recently, the company successfully secured €650k in funding to accelerate the commercial deployment of its groundbreaking antibiotic prescribing software, iAST®. This software, which obtained CE marking in July 2025, has garnered significant attention for its innovative approach to clinical decision-making in antibiotic prescription.

The funding round was spearheaded by First Drop, contributing €300k, and supported by Urriellu Ventures with an investment of €175k. Additionally, the round included an ENISA loan amounting to €180k, as well as the conversion of €162,500 in convertible notes from a previous round into equity.

Established in Oviedo in 2021, Pragmatech has quickly made a name for itself in the healthcare industry. The company’s flagship product, iAST®, stands out as the first AI-powered software in its category to receive CE marking. With a proven track record of reducing prescribing errors and recommending treatments with lower resistance potential, iAST® has positioned itself as a game-changer in clinical practice.

Speaking on the recent funding success, co-CEO of Pragmatech, Javier Fernández, expressed his gratitude, “With this funding round, we are strengthening our ability to bring iAST® to the hospitals and healthcare professionals who need it most. The support of investors like First Drop and Urriellu Ventures reinforces confidence in our technology and the positive impact it is having on clinical practice.”

Operating on a B2B model, Pragmatech aims to spearhead the digital transformation of infectious disease management, ultimately enhancing patient outcomes and boosting the sustainability of healthcare systems.

Pablo Valledor, co-CEO and CTO, emphasized the significance of the recent funding, stating, “This funding not only enables us to roll out iAST® at a commercial level, but also provides us with the resources necessary to continue refining our products and to ensure that artificial intelligence supports clinical decision-making in a safe and effective manner.”